Capital Structuring Review
For companies considering a capital raise that have yet to determine its quantum and form.
We advise healthcare and consumer health companies with enterprise values of US$5–75 million on capital raisings, acquisitions and divestments, and provide access to strategic and financial investors across Asia and Australia. Vietnam is our anchor market.
We are deliberately selective. We accept a limited number of mandates each year, and every engagement is partner-led from preparation through to completion.
For companies planning a capital raise or debt restructuring, from capital structure review to investor relations.
Capital advisoryFor strategic and financial investors entering Vietnam, from market assessment to signed acquisition.
For international investorsFor shareholders considering a sale: preparing the business first, then running a competitive process.
Sell-side advisoryThe first issue will be published in March 2027.
Our services span capital advisory, buy-side, sell-side, and valuation and intelligence. Engagements typically begin with capital structuring or value creation, so that a business approaches the market only when it is ready.
For companies considering a capital raise that have yet to determine its quantum and form.
For companies seeking growth capital, a debt restructuring, or both.
For companies that have recently closed a round and now report to institutional shareholders.
For foreign strategic and financial investors assessing entry into Vietnam.
For investors committed to Vietnam who need targets identified, approached and secured.
For shareholders planning a sale within 18–24 months whose business is not yet transaction-ready.
For shareholders who have resolved to sell all or a controlling interest.
For boards and shareholders who need a defensible valuation and structure for a negotiation or decision.
Periodic sector briefs on healthcare and consumer health in Vietnam and the region.
Each sub-sector has its own investor universe, valuation drivers and regulatory framework. We concentrate on two, so that every mandate is supported by genuine sector depth.
Where valuation expectations diverge from the market, or the financials are not yet ready for due diligence, we raise it early and recommend the preparatory work first.
We do not act on directly competing mandates in the same sub-sector at the same time.
All interests of our partners and advisers are disclosed in the engagement letter before work begins.
Legal, tax and specialist due diligence are undertaken by independent firms and coordinated by UCP.
For strategic and financial investors assessing healthcare or consumer health in Vietnam. The Market Entry Map provides the basis for deciding whether to enter, and how.
Size and structure of the sub-sector, key participants and degree of fragmentation
Regulatory framework and foreign ownership limits applicable to the sub-sector
Precedent transactions: acquirer, structure and disclosed valuation
20–30 potential targets, with scale, ownership and transaction readiness
Recommended entry route: acquisition, joint venture, distribution partnership or greenfield
Once the decision to enter Vietnam is made, the challenge is no longer information but access to the right decision-makers. We screen against agreed investment criteria, approach owners directly and manage the process through to signing.
Periodic sector briefs on healthcare and consumer health, with a focus on Vietnam and Southeast Asia: market structure, transaction activity, valuation benchmarks and regulatory developments.
Angelia Le founded UCP after more than fifteen years in M&A, private equity and venture capital across Asia-Pacific, complemented by direct experience building and operating consumer health businesses.
She established UCP to address a specific gap: founder-led healthcare businesses in Southeast Asia that require capital before they contemplate an exit, and an adviser able to bring Asian and Australian capital to the table.
Mr Thắng is Chairman of EHC Group, a Vietnamese healthcare technology company whose hospital information, electronic medical record, laboratory and imaging systems are deployed in more than 50 hospitals in Vietnam and abroad. He advises UCP on sector themes and due diligence in health technology and diagnostics.
Thảo is an investment, valuation and capital markets professional with more than nine years of experience across business valuation, investment advisory, M&A and corporate finance. A Chartered Valuation Surveyor (MRICS) and CFA charterholder, she has led valuations of more than 55 greenfield projects and 500 residential properties, as well as business and equity valuations across real estate, healthcare, pharmaceuticals, logistics and renewable energy.
Her transaction experience spans financial modelling, transaction advisory, strategic equity investments, corporate restructuring and debt financing, on transactions of up to US$52 million. In capital markets, she has structured financings, led capital raisings and investor relations programmes, and arranged loan and bond financings.
An initial meeting of 60–90 minutes, without fee or the need for an NDA, to explore whether there is a basis to work together. All discussions are held in confidence.
Or write to angelia.le@upsiloncapitalpartners.com